Ulcerative Colitis (Gastrointestinal) - Drugs In Development, 2021
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Drugs In Development, 2021, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 12, 56, 44, 4, 93 and 35 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 12 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Ulcerative Colitis (Gastrointestinal) - Drugs In Development, 2021
Table of Contents
Introduction
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Ulcerative Colitis - Therapeutics Assessment
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Ulcerative Colitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Ulcerative Colitis - Pipeline by 180 Life Corp, 2021
Ulcerative Colitis - Pipeline by 4D Pharma Plc, 2021
Ulcerative Colitis - Pipeline by 9 Meters Biopharma Inc, 2021
Ulcerative Colitis - Pipeline by AbbVie Inc, 2021
Ulcerative Colitis - Pipeline by Abivax SA, 2021
Ulcerative Colitis - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Affilogic SAS, 2021
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Akeso Inc, 2021
Ulcerative Colitis - Pipeline by Algernon Pharmaceuticals Inc, 2021
Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, 2021
Ulcerative Colitis - Pipeline by AltruBio Inc, 2021
Ulcerative Colitis - Pipeline by Alvotech ehf, 2021
Ulcerative Colitis - Pipeline by Am-Pharma BV, 2021
Ulcerative Colitis - Pipeline by Amgen Inc, 2021
Ulcerative Colitis - Pipeline by Amide Technologies Inc, 2021
Ulcerative Colitis - Pipeline by Apidel SA, 2021
Ulcerative Colitis - Pipeline by Applied Molecular Transport Inc, 2021
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, 2021
Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by AsiaBiome, 2021
Ulcerative Colitis - Pipeline by Asta Pharmaceuticals Co Ltd, 2021
Ulcerative Colitis - Pipeline by AstraZeneca Plc, 2021
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, 2021
Ulcerative Colitis - Pipeline by Avesthagen Ltd, 2021
Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Axim Biotechnologies Inc, 2021
Ulcerative Colitis - Pipeline by AzurRx BioPharma Inc, 2021
Ulcerative Colitis - Pipeline by Bacainn Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by BenevolentAI Ltd, 2021
Ulcerative Colitis - Pipeline by Bilix Co Ltd, 2021
Ulcerative Colitis - Pipeline by Bio-Thera Solutions Ltd, 2021
Ulcerative Colitis - Pipeline by BioGaia AB, 2021
Ulcerative Colitis - Pipeline by BioXpress Therapeutics SA, 2021
Ulcerative Colitis - Pipeline by Boehringer Ingelheim International GmbH, 2021
Ulcerative Colitis - Pipeline by Bridge Biotherapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Bristol Myers Squibb Co, 2021
Ulcerative Colitis - Pipeline by Captor Therapeutics SA, 2021
Ulcerative Colitis - Pipeline by Finch Therapeutics Group Inc, 2021
Ulcerative Colitis - Pipeline by First Wave Bio Inc, 2021
Ulcerative Colitis - Pipeline by FYB 202 GmbH & Co KG, 2021
Ulcerative Colitis - Pipeline by Fzata Inc, 2021
Ulcerative Colitis - Pipeline by Galapagos NV, 2021
Ulcerative Colitis - Pipeline by Genentech USA Inc, 2021
Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, 2021
Ulcerative Colitis - Pipeline by Giiant Pharma Inc, 2021
Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, 2021
Ulcerative Colitis - Pipeline by GLW Pharma, 2021
Ulcerative Colitis - Pipeline by Gossamer Bio Inc, 2021
Ulcerative Colitis - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2021
Ulcerative Colitis - Pipeline by Gusto Global LLC, 2021
Ulcerative Colitis - Pipeline by Hefei Cosource Pharmaceutical Inc, 2021
Ulcerative Colitis - Pipeline by Hillhurst Biopharmaceuticals Inc, 2021
Ulcerative Colitis - Pipeline by Himuka AM Pharma Corp, 2021
Ulcerative Colitis - Pipeline by Holy Stone Healthcare Co Ltd, 2021
Ulcerative Colitis - Pipeline by Hoth Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2021
Ulcerative Colitis - Pipeline by Ichnos Sciences Inc, 2021
Ulcerative Colitis - Pipeline by Iltoo Pharma, 2021
Ulcerative Colitis - Pipeline by Immix BioPharma Inc, 2021
Ulcerative Colitis - Pipeline by Immunic Inc, 2021
Ulcerative Colitis - Pipeline by Impetis Biosciences Ltd, 2021
Ulcerative Colitis - Pipeline by Inception Sciences Inc, 2021
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals Holding AB, 2021
Ulcerative Colitis - Pipeline by Innovation Pharmaceuticals Inc, 2021
Ulcerative Colitis - Pipeline by Innovative Pharmacological Research (IPHAR) Co Ltd, 2021
Ulcerative Colitis - Pipeline by Innovimmune Biotherapeutics Inc, 2021
Ulcerative Colitis - Pipeline by InSight Biopharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Intact Therapeutics, 2021
Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Intract Pharma Ltd, 2021
Ulcerative Colitis - Pipeline by Istesso Ltd, 2021
Ulcerative Colitis - Pipeline by Janux Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Ulcerative Colitis - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Ulcerative Colitis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Ulcerative Colitis - Pipeline by Johnson & Johnson, 2021
Ulcerative Colitis - Pipeline by Kaleido Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by Kiniksa Pharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by KoBioLabs Inc, 2021
Ulcerative Colitis - Pipeline by Korea Pharma Co Ltd, 2021
Ulcerative Colitis - Pipeline by Koutif Therapeutics LLC, 2021
Ulcerative Colitis - Pipeline by Kyorin Pharmaceutical Co Ltd, 2021
Ulcerative Colitis - Pipeline by Landos Biopharma Inc, 2021
Ulcerative Colitis - Pipeline by LegoChem Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by LG Chem Ltd, 2021
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co Ltd, 2021
Ulcerative Colitis - Pipeline by MAKScientific LLC, 2021
Ulcerative Colitis - Pipeline by Merck & Co Inc, 2021
Ulcerative Colitis - Pipeline by Mesoblast Ltd, 2021
Ulcerative Colitis - Pipeline by Metacrine Inc, 2021
Ulcerative Colitis - Pipeline by Metagen Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Microbiotica Ltd, 2021
Ulcerative Colitis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Ulcerative Colitis - Pipeline by Morphic Therapeutic Inc, 2021
Ulcerative Colitis - Pipeline by MRM Health NV, 2021
Ulcerative Colitis - Pipeline by Nano Intelligent Biomedical Engineering Corp, 2021
Ulcerative Colitis - Pipeline by Nektar Therapeutics, 2021
Ulcerative Colitis - Pipeline by NeuClone Pty Ltd, 2021
Ulcerative Colitis - Pipeline by Nexel Co Ltd, 2021
Ulcerative Colitis - Pipeline by Novan Inc, 2021
Ulcerative Colitis - Pipeline by Novartis AG, 2021
Ulcerative Colitis - Pipeline by Novellus Therapeutics Ltd, 2021
Ulcerative Colitis - Pipeline by Novome Biotechnologies Inc, 2021
Ulcerative Colitis - Pipeline by Nubiyota LLC, 2021
Ulcerative Colitis - Pipeline by Numedii Inc, 2021
Ulcerative Colitis - Pipeline by Nyrada Inc, 2021
Ulcerative Colitis - Pipeline by Oncodesign SA, 2021
Ulcerative Colitis - Pipeline by Oncostellae SL, 2021
Ulcerative Colitis - Pipeline by Oryn Therapeutics, 2021
Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, 2021
Ulcerative Colitis - Pipeline by Ovamed GmbH, 2021
Ulcerative Colitis - Pipeline by Palatin Technologies Inc, 2021
Ulcerative Colitis - Pipeline by Palo BioFarma SL, 2021
Ulcerative Colitis - Pipeline by PanTheryx Inc, 2021
Ulcerative Colitis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Pfizer Inc, 2021
Ulcerative Colitis - Pipeline by Pharmabiome AG, 2021
Ulcerative Colitis - Pipeline by Pharmapraxis, 2021
Ulcerative Colitis - Pipeline by Pharmaxis Ltd, 2021
Ulcerative Colitis - Pipeline by PNB Vesper Life Science Pvt Ltd, 2021
Ulcerative Colitis - Pipeline by Praeventix LLC, 2021
Ulcerative Colitis - Pipeline by Progenity Inc, 2021
Ulcerative Colitis - Pipeline by Prometheus Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by Protab Ltd, 2021
Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Protalix BioTherapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Provention Bio Inc, 2021
Ulcerative Colitis - Pipeline by Puretech Health Plc, 2021
Ulcerative Colitis - Pipeline by Qu Biologics Inc, 2021
Ulcerative Colitis - Pipeline by Re-Pharm Ltd, 2021
Ulcerative Colitis - Pipeline by Rebiotix Inc, 2021
Ulcerative Colitis - Pipeline by Regentys Corp, 2021
Ulcerative Colitis - Pipeline by Reistone Biopharma Co Ltd, 2021
Ulcerative Colitis - Pipeline by RhemaStem SRLS, 2021
Ulcerative Colitis - Pipeline by Rhizen Pharmaceuticals SA, 2021
Ulcerative Colitis - Pipeline by Salix Pharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Samsung Bioepis Co Ltd, 2021
Ulcerative Colitis - Pipeline by Saniona AB, 2021
Ulcerative Colitis - Pipeline by Santhera Pharmaceuticals Holding AG, 2021
Ulcerative Colitis - Pipeline by Sareum Holdings Plc, 2021
Ulcerative Colitis - Pipeline by Semorex Technologies Ltd, 2021
Ulcerative Colitis - Pipeline by Senda Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by Seres Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by Servatus Ltd, 2021
Ulcerative Colitis - Pipeline by Shanghai Jiyu Pharmaceutical Technology Co Ltd, 2021
Ulcerative Colitis - Pipeline by Shaperon Inc, 2021
Ulcerative Colitis - Pipeline by Siam Bioscience Co Ltd, 2021
Ulcerative Colitis - Pipeline by StemRIM Inc, 2021
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, 2021
Ulcerative Colitis - Pipeline by Sublimity Therapeutics HoldCo Ltd, 2021
Ulcerative Colitis - Pipeline by Suono Bio Inc, 2021
Ulcerative Colitis - Pipeline by Surrozen Inc, 2021
Ulcerative Colitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Swedish Orphan Biovitrum AB, 2021
Ulcerative Colitis - Pipeline by Synedgen Inc, 2021
Ulcerative Colitis - Pipeline by Synlogic Inc, 2021
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Ulcerative Colitis - Pipeline by Tarus Therapeutics Inc, 2021
Ulcerative Colitis - Pipeline by TheraSource LLC, 2021
Ulcerative Colitis - Pipeline by Theravance Biopharma Inc, 2021
Ulcerative Colitis - Pipeline by Thetis Pharmaceuticals LLC, 2021
Ulcerative Colitis - Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2021
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, 2021
Ulcerative Colitis - Pipeline by TopiVert Ltd, 2021
Ulcerative Colitis - Pipeline by Torrent Pharmaceuticals Ltd, 2021
Ulcerative Colitis - Pipeline by Vedanta Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by Ventyx Biosciences Inc, 2021
Ulcerative Colitis - Pipeline by Vivreon Biosciences LLC, 2021
Ulcerative Colitis - Pipeline by Voronoi Group, 2021
Ulcerative Colitis - Pipeline by Zhiyi Pharmaceuticals Inc, 2021
Ulcerative Colitis - Dormant Projects, 2021
Ulcerative Colitis - Dormant Projects, 2021 (Contd..1)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..2)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..3)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..4)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..5)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..6)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..7)
Ulcerative Colitis - Dormant Projects, 2021 (Contd..8)
Ulcerative Colitis - Discontinued Products, 2021
Ulcerative Colitis - Discontinued Products, 2021 (Contd..1)
Ulcerative Colitis - Discontinued Products, 2021 (Contd..2)
List of Figures
Number of Products under Development for Ulcerative Colitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 110
According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period.
The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
Global Lansoprazole Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 102
The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the comp......
Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 88
According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period.
The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
Global Esomeprazole Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 89
The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the comp......
Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 02-Jan-2024 Price: US 3380 Onwards Pages: 126
Market Overview of Global Irritable Bowel Syndrome (IBS) market:
According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 28-Dec-2023 Price: US 3380 Onwards Pages: 109
Market Overview of Global Diarrhea Drug market:
According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 96
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 3280 Onwards Pages: 136
Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 113
Market Overview of Global Pentasa (Ulcerative Colitis) market:
According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
